目的探讨高龄老年冠心病患者行冠状动脉介入治疗(PCI)的临床特点和远期预后。方法连续纳入于2013年1—12月行PCI治疗的老年冠心病患者2981例,比较其中普通老年患者(65~74岁, n =2300,普通组)与高龄老年患者(≥75岁, n =681,高龄组)的临...目的探讨高龄老年冠心病患者行冠状动脉介入治疗(PCI)的临床特点和远期预后。方法连续纳入于2013年1—12月行PCI治疗的老年冠心病患者2981例,比较其中普通老年患者(65~74岁, n =2300,普通组)与高龄老年患者(≥75岁, n =681,高龄组)的临床特点及PCI术后2年随访期间的临床预后情况。结果高龄组BMI、左室射血分数(LVEF)、术前肾小球滤过率(eGFR)、使用钙离子拮抗剂等以及冠状介入情况(经桡动脉途径等)的比例较普通组低( P <0.05);既往PCI史、使用质子泵抑制剂等的比例以及冠状动脉病变情况(左主干病变、右冠状动脉病变、术前SYNTAX评分、严重钙化病变等)较普通组高( P <0.05)。2年随访结果显示,高龄组全因死亡、心源性死亡以及支架内血栓的发生率明显高于普通组( P <0.05);主要不良心脑血管事件、再发心肌梗死、血运重建(靶血管和靶病变血运重建)、脑卒中、出血以及大出血的发生率比较,2组差异无统计学意义( P >0.05)。高龄组中,女性全因死亡、心源性死亡以及再发心肌梗死的发生率明显高于男性( P <0.05)。单因素和多因素COX回归分析显示,术后2年随访期间,年龄是老年冠心病患者发生支架内血栓的独立危险因素( P <0.05),不是全因死亡以及心源性死亡的独立危险因素( P >0.05);既往脑血管病史是全因死亡的独立危险因素( P <0.05);使用主动脉内球囊反搏(IABP)、较好的心肾功能、经桡动脉途径是全因死亡以及心源性死亡的独立保护因素( P <0.05);女性是高龄患者全因死亡的独立危险因素( P <0.05),不是心源性死亡和再发心肌梗死的独立危险因素( P > 0.05)。结论高龄老年冠心病患者合并较差的心肾功能以及程度较重的冠状动脉病变。PCI术后2年随访期间:1)全因死亡、心源性死亡以及支架内血栓的发生率较高。2)经校正多种危险因素后,年龄不是老年冠心病患者全因死亡以及心源性死亡的独立危险因素,而是支架内血栓的独立危险因素;女性是高龄老年冠心病患者全因死亡的独立危险因素,不是心源性死亡和再发心肌梗死的独立危险因素。展开更多
目的分析我国老年人高血压的患病率,以及知晓、治疗和控制状况。方法使用2012-2015年全国高血压分层多阶段随机抽样横断面调查资料[国家"十二五"科技支撑计划项目"中国重要心血管病调查及关键技术研究"]进行分析,...目的分析我国老年人高血压的患病率,以及知晓、治疗和控制状况。方法使用2012-2015年全国高血压分层多阶段随机抽样横断面调查资料[国家"十二五"科技支撑计划项目"中国重要心血管病调查及关键技术研究"]进行分析,其中老年人(年龄≥60岁)134 397人。老年人高血压定义为平均收缩压≥140和(或)舒张压≥90 mm Hg或近2周内服用降压药物;单纯收缩期高血压定义为收缩压≥140和舒张压<90 mm Hg,单纯舒张期高血压定义为收缩压<140和舒张压≥90 mm Hg,血压控制定义为收缩压<140和舒张压<90 mm Hg。结果我国老年人高血压患病率为53.24%(约9450万人),单纯收缩期高血压患病率为30.33%(约5380万人),单纯舒张期高血压患病率为1.32%(约234万人),单纯收缩期高血压占老年高血压总人数的56.95%。城市和农村居民的老年高血压患病率比较,差异无统计学意义(53.38%比53.20%,P=0.904),但女性高于男性(55.28%比51.14%,P<0.001)。在老年高血压患者中,知晓率57.08%,治疗率51.35%,控制率仅18.20%。结论老年人高血压知晓、治疗和控制率有所提高,但整体仍低。展开更多
Background Multiple randomized clinical trials have demonstrated that drug eluting stents can significantly reduce the rates of restenosis and subsequent adverse events across lesion and patient. We investigated the m...Background Multiple randomized clinical trials have demonstrated that drug eluting stents can significantly reduce the rates of restenosis and subsequent adverse events across lesion and patient. We investigated the medium term clinical efficacy and safety of Firebird sirolimus eluting stent （SES） in coronary artery disease. Methods The sample was 509 consecutive patients with coronary artery disease （CAD） who were treated by Firebird SES and finished three-year clinical follow-up. The occurrences of major adverse cardiac events （MACE） and Academic Research Consortium defined stent thrombosis （ST） were evaluated in patients with and without diabetes mellitus. Results Three hundred and thirty three patients （65. 4%） were treated by Firebird SES by off label indications. Angiographic success was achieved in 98.3% of the lesions. MACE and target vessel revascularization rates at 6-month, 1 year＇s and 3 years＇ clinical follow-up were 2.4% and 1.4%, 4.1% and 2.8%, 7.9% and 5.1%, respectively. The cumulative 3-year MACE free survival rate was 92.1%. After 3 years, DM patients had significantly higher rates of MACE （13.7% vs 6.4%, P 〈0.05） and TVR （9.8% vs 4.0%, P 〈0.05） and the cumulative MACE free survival rate was very significantly lower in the DM group （86.4% vs 93;6%, P 〈0.05）. ST occurred in 7 patients （1.4%） at the end of 3 years＇ follow-up, 5 of them had definite ST with 4 cases presenting with myocardial reinfarction and 1 with unstable angina, the other 2 with probable ST had reinfarction in the stented coronary territory without angiographic follow-up. There was no difference in occurrence of ST between off label （1.5%） and on label groups （1.1%, P=-0.07）. Conclusions In daily practice, about 2/3 of patients were treated by Firebird SES by off label indications. Medium term clinical follow-up of 3 years indicated CAD patients treated by Firebird SES had a low MACE and acceptable ST rate. DM patients had higher rates of adverse events and than non DM.展开更多
Background Treatment of ischemic heart disease remains an important challenge, though there have been enormous progresses in cardiovascular therapeutics. This study was conducted to evaluate whether Tongxinluo （TXL）...Background Treatment of ischemic heart disease remains an important challenge, though there have been enormous progresses in cardiovascular therapeutics. This study was conducted to evaluate whether Tongxinluo （TXL） treatment around the transplantation of mesenchymal stem cells （MSCs） can improve survival and subsequent activities of implanted cells in swine hearts with acute myocardial infarction （AMI） and reperfusion. Methods Twenty-eight Chinese mini-pigs were divided into four groups including a control group （n=7）; group 2, administration of low-close TXL alone from the 3rd day prior to AMI to the 4th day post transplantation （n=-7）; group 3, MSCs alone （n=-7） and group 4, TXL ＋ MSCs （n=7）. AMI models were made by occlusion of the left anterior descending coronary artery for 90 minutes. Autologous bone marrow-MSCs （3×10^7 cells/animal） were then injected into the post-infarct myocardium immediately after AMI and reperfusion. The survival and differentiation of implanted cells in vivo were detected by immunofluorescent analysis. The data of cardiac function were obtained at baseline （1 week after transplantation） and endpoint （6 weeks after transplantation） by single photon emission computed tomography （SPECT） and magnetic resonance imaging （MRI）. Apoptosis was detected by TUNEL assay and the oxidative stress level was investigated in the post-infarct myocardium at endpoint. Results At endpoint, there was less fibrosis and inflammatory cell infiltration with more surviving myocardium in group 4 than in the control group. In group 4 the survival and differentiation of implanted MSCs were significantly improved more than that seen in group 3 alone （P〈0.0001）; the capillary density was also significantly greater than in the control group, group 2 or 3 both in the infarcted zone （P〈0.0001） and the peri-infarct zone （P〈0.0001）. MRI showed that parameters at baseline were not significantly different between the 4 groups. At endpoint, regional wall thickening and the left ventricular ejection fraction were increased while the left ventricular mass index, dyskinetic segments and infarcted size were decreased only in group 4 compared with control group （P〈0.0001）. SPECT showed that the area of perfusion defect was significantly decreased at endpoint only in group 4 compared with control group （P〈0.0001）. TUNEL assay indicated that TXL administration significantly decreased cell apoptosis in peri-infarct myocardium in groups 2 and 4. Furthermore, superoxide dismutase （SOD） significantly increased and malondialdehyde （MDA） decreased in groups 2 and 4 by the administration of TXL. Conclusions Our study demonstrates the following： （1） immediate intramyocardial injection of MSCs after AMI and reperfusion resulted in limited survival and differentiation potential of implanted cells in vivo, thus being incapable of beneficially affecting post-hearts; （2） TXL-facilitation resulted in a significant survival and differentiation potential of implanted cells in vivo via inhibition of apoptosis and oxidative stress, accompanied by significant benefits in cardiac function.展开更多
文摘目的探讨高龄老年冠心病患者行冠状动脉介入治疗(PCI)的临床特点和远期预后。方法连续纳入于2013年1—12月行PCI治疗的老年冠心病患者2981例,比较其中普通老年患者(65~74岁, n =2300,普通组)与高龄老年患者(≥75岁, n =681,高龄组)的临床特点及PCI术后2年随访期间的临床预后情况。结果高龄组BMI、左室射血分数(LVEF)、术前肾小球滤过率(eGFR)、使用钙离子拮抗剂等以及冠状介入情况(经桡动脉途径等)的比例较普通组低( P <0.05);既往PCI史、使用质子泵抑制剂等的比例以及冠状动脉病变情况(左主干病变、右冠状动脉病变、术前SYNTAX评分、严重钙化病变等)较普通组高( P <0.05)。2年随访结果显示,高龄组全因死亡、心源性死亡以及支架内血栓的发生率明显高于普通组( P <0.05);主要不良心脑血管事件、再发心肌梗死、血运重建(靶血管和靶病变血运重建)、脑卒中、出血以及大出血的发生率比较,2组差异无统计学意义( P >0.05)。高龄组中,女性全因死亡、心源性死亡以及再发心肌梗死的发生率明显高于男性( P <0.05)。单因素和多因素COX回归分析显示,术后2年随访期间,年龄是老年冠心病患者发生支架内血栓的独立危险因素( P <0.05),不是全因死亡以及心源性死亡的独立危险因素( P >0.05);既往脑血管病史是全因死亡的独立危险因素( P <0.05);使用主动脉内球囊反搏(IABP)、较好的心肾功能、经桡动脉途径是全因死亡以及心源性死亡的独立保护因素( P <0.05);女性是高龄患者全因死亡的独立危险因素( P <0.05),不是心源性死亡和再发心肌梗死的独立危险因素( P > 0.05)。结论高龄老年冠心病患者合并较差的心肾功能以及程度较重的冠状动脉病变。PCI术后2年随访期间:1)全因死亡、心源性死亡以及支架内血栓的发生率较高。2)经校正多种危险因素后,年龄不是老年冠心病患者全因死亡以及心源性死亡的独立危险因素,而是支架内血栓的独立危险因素;女性是高龄老年冠心病患者全因死亡的独立危险因素,不是心源性死亡和再发心肌梗死的独立危险因素。
文摘目的血小板功能检测指导心脏外科手术治疗的价值,目前仍存在争议,相关研究的中国患者的数据较少。本文旨在探讨血栓弹力图(TEG)对CABG术后输血的预测价值。方法入选阜外医院61例行CABG的患者,所有患者术前24 h内行TEG检测,临床主要终点为术后输血。结果CABG术后输血共14人(23.0%)。输血组患者TEG检测的平均二磷酸腺苷诱导的血凝块最大强度[MA(ADP)]值显著低于未输血组(28.67±18.04 vs 37.21±12.64,P=0.023)。选取MA(ADP)值31mm为划分点,≤31mm组患者术后输血风险明显较>31mm组增高(37.5%vs 13.5%,P=0.030)。多因素回归分析显示MA(ADP)≤31mm为CABG术后输血的独立预测因素,MA(ADP)≤31mm患者术后输血的风险是MA(ADP)>31mm患者的8.352倍(95%CI:1.670-41.780,P=0.010)。结论TEG血小板功能检测对CABG术后出血有一定的预测价值;MA(ADP)≤31mm为CABG术后输血的独立危险因素。
文摘目的分析我国老年人高血压的患病率,以及知晓、治疗和控制状况。方法使用2012-2015年全国高血压分层多阶段随机抽样横断面调查资料[国家"十二五"科技支撑计划项目"中国重要心血管病调查及关键技术研究"]进行分析,其中老年人(年龄≥60岁)134 397人。老年人高血压定义为平均收缩压≥140和(或)舒张压≥90 mm Hg或近2周内服用降压药物;单纯收缩期高血压定义为收缩压≥140和舒张压<90 mm Hg,单纯舒张期高血压定义为收缩压<140和舒张压≥90 mm Hg,血压控制定义为收缩压<140和舒张压<90 mm Hg。结果我国老年人高血压患病率为53.24%(约9450万人),单纯收缩期高血压患病率为30.33%(约5380万人),单纯舒张期高血压患病率为1.32%(约234万人),单纯收缩期高血压占老年高血压总人数的56.95%。城市和农村居民的老年高血压患病率比较,差异无统计学意义(53.38%比53.20%,P=0.904),但女性高于男性(55.28%比51.14%,P<0.001)。在老年高血压患者中,知晓率57.08%,治疗率51.35%,控制率仅18.20%。结论老年人高血压知晓、治疗和控制率有所提高,但整体仍低。
文摘Background Multiple randomized clinical trials have demonstrated that drug eluting stents can significantly reduce the rates of restenosis and subsequent adverse events across lesion and patient. We investigated the medium term clinical efficacy and safety of Firebird sirolimus eluting stent （SES） in coronary artery disease. Methods The sample was 509 consecutive patients with coronary artery disease （CAD） who were treated by Firebird SES and finished three-year clinical follow-up. The occurrences of major adverse cardiac events （MACE） and Academic Research Consortium defined stent thrombosis （ST） were evaluated in patients with and without diabetes mellitus. Results Three hundred and thirty three patients （65. 4%） were treated by Firebird SES by off label indications. Angiographic success was achieved in 98.3% of the lesions. MACE and target vessel revascularization rates at 6-month, 1 year＇s and 3 years＇ clinical follow-up were 2.4% and 1.4%, 4.1% and 2.8%, 7.9% and 5.1%, respectively. The cumulative 3-year MACE free survival rate was 92.1%. After 3 years, DM patients had significantly higher rates of MACE （13.7% vs 6.4%, P 〈0.05） and TVR （9.8% vs 4.0%, P 〈0.05） and the cumulative MACE free survival rate was very significantly lower in the DM group （86.4% vs 93;6%, P 〈0.05）. ST occurred in 7 patients （1.4%） at the end of 3 years＇ follow-up, 5 of them had definite ST with 4 cases presenting with myocardial reinfarction and 1 with unstable angina, the other 2 with probable ST had reinfarction in the stented coronary territory without angiographic follow-up. There was no difference in occurrence of ST between off label （1.5%） and on label groups （1.1%, P=-0.07）. Conclusions In daily practice, about 2/3 of patients were treated by Firebird SES by off label indications. Medium term clinical follow-up of 3 years indicated CAD patients treated by Firebird SES had a low MACE and acceptable ST rate. DM patients had higher rates of adverse events and than non DM.
基金This work was supported by the grants from the National Basic Research Program(973 Program)Ministry of Science and Technology,China(No.2005CB523303)
文摘Background Treatment of ischemic heart disease remains an important challenge, though there have been enormous progresses in cardiovascular therapeutics. This study was conducted to evaluate whether Tongxinluo （TXL） treatment around the transplantation of mesenchymal stem cells （MSCs） can improve survival and subsequent activities of implanted cells in swine hearts with acute myocardial infarction （AMI） and reperfusion. Methods Twenty-eight Chinese mini-pigs were divided into four groups including a control group （n=7）; group 2, administration of low-close TXL alone from the 3rd day prior to AMI to the 4th day post transplantation （n=-7）; group 3, MSCs alone （n=-7） and group 4, TXL ＋ MSCs （n=7）. AMI models were made by occlusion of the left anterior descending coronary artery for 90 minutes. Autologous bone marrow-MSCs （3×10^7 cells/animal） were then injected into the post-infarct myocardium immediately after AMI and reperfusion. The survival and differentiation of implanted cells in vivo were detected by immunofluorescent analysis. The data of cardiac function were obtained at baseline （1 week after transplantation） and endpoint （6 weeks after transplantation） by single photon emission computed tomography （SPECT） and magnetic resonance imaging （MRI）. Apoptosis was detected by TUNEL assay and the oxidative stress level was investigated in the post-infarct myocardium at endpoint. Results At endpoint, there was less fibrosis and inflammatory cell infiltration with more surviving myocardium in group 4 than in the control group. In group 4 the survival and differentiation of implanted MSCs were significantly improved more than that seen in group 3 alone （P〈0.0001）; the capillary density was also significantly greater than in the control group, group 2 or 3 both in the infarcted zone （P〈0.0001） and the peri-infarct zone （P〈0.0001）. MRI showed that parameters at baseline were not significantly different between the 4 groups. At endpoint, regional wall thickening and the left ventricular ejection fraction were increased while the left ventricular mass index, dyskinetic segments and infarcted size were decreased only in group 4 compared with control group （P〈0.0001）. SPECT showed that the area of perfusion defect was significantly decreased at endpoint only in group 4 compared with control group （P〈0.0001）. TUNEL assay indicated that TXL administration significantly decreased cell apoptosis in peri-infarct myocardium in groups 2 and 4. Furthermore, superoxide dismutase （SOD） significantly increased and malondialdehyde （MDA） decreased in groups 2 and 4 by the administration of TXL. Conclusions Our study demonstrates the following： （1） immediate intramyocardial injection of MSCs after AMI and reperfusion resulted in limited survival and differentiation potential of implanted cells in vivo, thus being incapable of beneficially affecting post-hearts; （2） TXL-facilitation resulted in a significant survival and differentiation potential of implanted cells in vivo via inhibition of apoptosis and oxidative stress, accompanied by significant benefits in cardiac function.
